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Available online 26 April 2016Clinical research activities at academicmedical centers are challenging to oversee.Without effective research ad-
ministration, a continually evolving set of regulatory and institutional requirements can divert investigator and
study team attention away from a focus on scientiﬁc gain, study conduct, and patient safety. However, even
when the need for research administration is recognized, there can be struggles over what form it should take.
Central research administration may be viewed negatively, with individual groups preferring to maintain auton-
omy over processes. Conversely, a proliferation of individualized approaches across an institution can create in-
efﬁciencies or invite risk.
This article describes experiences establishing a uniﬁed research support ofﬁce at the Duke University School of
Medicine based on a framework of customer support. The Duke Ofﬁce of Clinical Research was formed in 2012
with a vision that research administration at academicmedical centers should help clinical investigators navigate
the complex research environment and operationalize research ideas. The ofﬁce provides an array of services that
have received high satisfaction ratings. The authors describe the ongoing culture change necessary for success of
the uniﬁed research support ofﬁce. Lessons learned from implementation of the Duke Ofﬁce of Clinical Research
may serve as a model for other institutions undergoing a similar transition.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Academic medical center1. Introduction
With direct access to patients and clinical investigatorswho fuel and
test new ideas, academicmedical centers (AMCs) play an important role
in innovation that improves patient care and health outcomes [1]. How-
ever, an increasingly complex environment for clinical research in
healthcare delivery settings could threaten this path to discovery if inef-
ﬁciencies are not addressed [2–4]. Challenges facing clinical investiga-
tors include lack of time for research due to demands of clinical
practice; disruption in established workﬂows associated with a transi-
tion to electronic medical records; insufﬁcient infrastructure; and
expanding complexities of data collection, government and institutional
regulation, and burdensome contract negotiation [3,5–7]. As summa-
rized in a 2015 National Academies report, “continuing expansion of
the federal regulatory system and its ever-growing requirements are
diminishing the effectiveness of the nation's research investment by
directing investigators' time away from research and training toward
overlapping and incongruent administrative matters.” [8] Many associ-
ate an increase in administrative burden with discouraging clinicians
from pursuing a career in research, resulting in a shortage that couldearch (DOCR), Duke University
Hock Plaza, 9044), Durham, NC
).
. This is an open access article underjeopardize the clinical research enterprise [4,7,8]. These challenges un-
derscore the need for expert assistance from clinical research adminis-
trative support so clinical investigators can focus on science that will
lead to improved patient care and health outcomes.
Compared with a traditional model in which the management of
studies is performed in a coordinator/investigator unit responsible for
all trial activities, there is a growing interest inwhether consolidating re-
search administration and support activities within a department or in-
stitution may contribute to more effective infrastructure for clinical
research [9]. However, barriers to implementing uniﬁed support systems
may include lack of faculty support due to perceived loss of autonomy in
research conduct [10]. Detailed accounts are needed of transitions to uni-
ﬁed research support ofﬁces, along with data to evaluate the potential
beneﬁts and limitations of such a model. This article reviews the Duke
University School of Medicine experiencewith developing a centralized,
support-oriented approach to managing clinical research.
2. Case study: Duke Ofﬁce of Clinical Research
2.1. Transition to a uniﬁed support ofﬁce
The transition to a uniﬁed research support ofﬁce occurred gradual-
ly. Because of the proliferation of one-off approaches to institutional
support for study teams, Duke created infrastructure and policy changesthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Organization of (A) the initial Clinical Research Support Ofﬁce and (B) the subsequent uniﬁed/expanded Duke Ofﬁce of Clinical Research. The Duke Ofﬁce of Clinical Research
replaced the Clinical Research Support Ofﬁce in 2012, offering additional services and greater harmonization of administrative support. The Duke Ofﬁce of Clinical Research liaises with
multiple other central ofﬁces, as well as faculty, staff, and students across Duke Health and Duke University. Investigators and research teams are supported throughout study
planning, conduct, and close-out. CRSO, Clinical Research Support Ofﬁce; CTMS, clinical trial management system; EHR, electronic health record; FTE, full-time equivalent; IRB,
institutional review board; SOP, standard operating procedure.
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research. The changes were originally carried out under the Vice Dean
for Research, who oversaw both clinical and basic research. Duke ﬁrst
created oversight bodies in the disease-based clinical departments and
institutes. These Clinical Research Units (CRUs) were initially focused
on addressing industry-sponsored trial oversight andmanagement. Re-
gardless of size, each CRU created a charter, named a director, research
practice manager, and ﬁnancial practice manager. The CRUs were sup-
ported by a narrowly scoped Clinical Research Support Ofﬁce (Fig.
1A); this central administration ofﬁce pushed business processes and
responsibility to the CRUs and served as a pass-through checkpoint. Al-
though there was a marked beneﬁt in oversight and compliance at the
onset (e.g., improvements in clinical research billing, increased focus
on training), with time this model became problematic. There was a
lack of consistent processes across CRUs, given that each could establish
policies and procedures unique to the history of the unit. These incon-
sistent policies (e.g., differences in clinical research training require-
ments, variations in feasibility review) created confusion for faculty
performing research in multiple CRUs.
After years ofmandates, poor customer service, faculty isolation, and
inconsistent study management at the CRU level, the institution
established the role of Vice Dean for Clinical Research to improve pro-
cesses and communication involving the CRUs and central administra-
tion. Organizational changes included new reporting structures for the
Institutional Review Board, Clinical Research Support Ofﬁce, regulatoryaffairs (IND/IDE management), and research integrity. The key cultural
change involved rebranding the Clinical Research Support Ofﬁce by
expanding the concept and scope of an established Research Manage-
ment Team from the Duke University School of Nursing [11]. The Re-
search Management Team originally provided ﬂexible, cost-efﬁcient
institutional support for research coordination, data management, and
informatics. Its “study teams as my customer” approach served as a
proof-of-concept model for what would become the new Duke Ofﬁce
of Clinical Research (DOCR; Fig. 1B). In 2012, the ResearchManagement
Team's leader was installed as the director of DOCR to reinvigorate re-
search support under the new ofﬁce.
Key changes included bringing senior information technology ex-
pertise to bolster support for clinical research software applications
and reporting [11], establishing a new position to liaise with contracts
and ﬁnance departments, and creating designated staff to handle
ClinicalTrials.gov registrations and reporting [12]. DOCR increased
from 14 to 54 full-time staff members over 3 years and now provides
a broad range of support services (Figs. 1B, 2). Some research support
remains within the individual CRUs, which vary in size and scope, but
the strengthened uniﬁed support ofﬁce provides access to consistent
navigation, tools, and training for the N700 clinical research coordina-
tors and other research support staff throughout the institution. DOCR's
mission is to improve patient care through outstanding clinical research
that is supported by sustainable business processes and a well-trained
clinical research workforce.
Fig. 2. Array of services offered by the Duke Ofﬁce of Clinical Research.
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DOCR services span the stages of a clinical study and are supported
by staff conducting a range of activities, including study startup, re-
search builds in the electronic health record, and outreach andmentor-
ship (Figs. 1B, 2). Studies that will be billing any research costs through
the Duke University Health System are required to have a study initia-
tion meeting with DOCR to review the protocol for clinical and
research-speciﬁc activities, identify needs for the electronic health re-
cord (e.g., order sets, billing calendar), review qualifying status and na-
tional coverage decisions, and identify funding for activities and
coverage of related activities in alignment with health system ﬁnancial
policies. Use of all other DOCR services is voluntary.
During study planning, investigators may receive a free consultation
(subsidized by the School of Medicine and Duke Clinical and Transla-
tional Science Award [CTSA]) to determine project needs, and an esti-
mate for DOCR services is provided. In this way, DOCR is able to tailor
support to the needs of the individual study and research team. For ex-
ample, experienced and well-staffed study teams conducting industry-
sponsored studies may need little assistance from DOCR. In contrast,
an investigator-initiated NIH-funded study is likely to have a different
set of needs. Aside from the initial study planning meeting, requests
also may be submitted at any time through a central DOCR email ad-
dress. DOCR publicizes its services on its website, through regular pre-
sentations, and via interactions with study teams (i.e., word of mouth).
As a uniﬁed research support ofﬁce, DOCR is able to offer a wide
range of services. Many DOCR staff are cross-trained, enabling an efﬁ-
cient infrastructure that can meet the objectives of multiple research
programs. Some investigators have indicated that they would not
have felt comfortable supporting full-time research administrative
staff within a small group due to uncertainties of future funding. By pro-
viding partial effort with speciﬁc spheres of expertise, we hypothesize
that investigators will be less likely to assign tasks to an employee
with insufﬁcient background (e.g., a coordinator assigned the additional
role of data management). This DOCR shared service model allows re-
searchers to more tightly manage labor expenditures by only paying
for services when they are needed. The shared-effort coordinator and
datamanagement pools reduce pressure from investigators and provide
job security for highly skilled staff, which allows the institution to devel-
op and retain top talent.Workloads can be adjusted to prevent burnout,
a common problem encountered with research coordinators in AMCs
[13]. Additionally, managing staff can relieve faculty from the burden
of addressing any performance issues. Finally, this service can providea quick stopgap in the event that a research team unexpectedly loses
some of its staff during a study. This stafﬁng model therefore beneﬁts
both the researchers and administration.
In general, requests for datamanagement or clinical research coordi-
nator effort are submitted via a Research Electronic Data Capture (RED-
Cap) survey for that purpose. Requests also may come in via direct
contact with a DOCR director, associate director, or Research Manage-
ment Team member. A DOCR associate director contacts the study
team to assess the effort needed, records the information in the DOCR
effort database, and generates an agreement to send to the study team.
DOCR provides free guidance on study design, protocol writing, and
institutional review board submission to all Duke residents and fellows.
We believe these services help establish positive relationships with
DOCR early and will ultimately lead to higher quality research conduct
at the institution.
The theme of facilitation and navigation is central to DOCR services
(Fig. 2). It liaises with the CRUs and other institutional ofﬁces to shep-
herd studies throughout their life cycle. Close ties at the leadership
level with the School of Medicine Finance Ofﬁce, Ofﬁce of Research In-
formatics, and Institutional Review Board, among others, help maintain
productive partnerships (Fig. 1). Parallel processes are initiated when-
ever possible to avoid delays; for example, an operational review can
be conducted concurrent with institutional review board review and
contract negotiation. Even where support services reside within other
groups, DOCR strives to add value through coordination and communi-
cation. A communications teamproduces newsletters on relevant topics
for faculty, research staff, and CRU leadership; topics are gathered from
all research administrative ofﬁces. Furthermore, DOCR attends regular
meetingswith stakeholder groups to engage around initiatives, policies,
or procedures that may involve multiple stakeholders.2.3. Operations
DOCR shares an administrative manager with the Ofﬁce of Research
Informatics, who assists with budgets and ﬁnance. Projects and effort
are tracked in an internal database, and stafﬁng is increased as needed
to keep up with demand and prevent burnout. When DOCR rebooted,
CRU staff were not absorbed, but they were eligible to apply for open
DOCR positions. Turnover has been minimal within DOCR, though
some staff do leave or go on to other positions within the institution.
DOCR is a leader in developing staff and encourages staff to consider
well-matched opportunities across Duke.
Fig. 3. Satisfaction with DOCR services as assessed by (A, B) annual survey and (C, D) survey after support completed by DOCR's Research Management Team. Panel A shows quantitative
data from the annual survey. For panel B, free-text comments entered during survey completionwere assessed by a group of 8 DOCR staff to assign as positive or negative. Commentswere
anonymous and blinded to year. Panels C and D, respectively, show survey ratings after completion of DOCR data management and CRC support; data are from a one-year period from
March 2015 to March 2016. CRC, clinical research coordinator; DOCR, Duke Ofﬁce of Clinical Research; FY, ﬁscal year; RMT, Research Management Team.
142 D.C. Snyder et al. / Contemporary Clinical Trials 48 (2016) 139–1452.4. Training/professional development
An important facet of the uniﬁed support ofﬁce is to contribute to
the growth of a network of research professionals. In 2015, DOCR of-
fered N300 classes on topics including human subjects research, study
documentation, and data security. There were over 13,000 individual
completions across the in-person, blended, and online courses. DOCR
not only offers training, but also an opportunity for advancement that
was not previously available tomany clinical research staff. Skilled coor-
dinators working under a single principal investigator may not envision
a path for professional growth within the institution, and may feel
pressured by the investigator to remain stagnant within a uniquely de-
ﬁned position. By harmonizing research support, a new avenue for ca-
reer development is opened, and the institution can provide support
and structure to assist future generations of research professionals in
becoming leaders who are truly invested in team research. Potential
for career progression also helps establish clinical research professionals
as leading practitioners in the clinical research industry. In support of
this, DOCR currently is leading a project to modernize all job descrip-
tions for research staff in the School of Medicine. Job levels will be stan-
dardized across the institution and based on education, experience, and
workforce competencies, and will allow for individual professional
growth [14]. In concert with this effort, human resources is conducting
a market analysis of salaries. DOCR also launched a voluntary Research
Professionals Network at Duke in 2014 that so far has N400 members.
The network connects research professionals from across the institution
to advocate for research careers, provide options for formal and infor-
mal education, and develop high standards in the research community.3. Results
3.1. Efﬁciency
Although no speciﬁc efﬁciency goals were established when DOCR
rebooted clinical research support, the ofﬁce has been tracking data
and monitoring improvements to establish ongoing metrics. Whenfocusing on studies that were required to have a study initiation meet-
ing with DOCR, decreases in the institutional review time are not yet
demonstrated, but a decrease in the time from institutional approval
until the ﬁrst participant is consented has been observed (Table 1). By
continuing to provide expert navigation and better prepare research
teams, DOCR aims to continue to improve these timelines. Importantly,
there has been a reduction in the percentage of these studies that close
without consenting any patients (Table 2), which could signify a more
effective review process that is selective of research likely to be success-
fully implemented. The overall number of clinical research studies, aver-
age number of patients accrued per enrolling study, and total number of
patients enrolled across the institution increased over time; the types of
studies remained constant (Table 3). During the period from 2011 to
2015, the percentage of patients seen in the health system who were
enrolled in clinical research increased from 1% to 7%; this exceeded
the goal of increasing enrollment by 5%.
One of the ways DOCR has increased efﬁciency is in the contracts
process. A common complaint heard by School of Medicine leadership
from facultywas how long it took for a contract to be negotiated and ex-
ecuted at Duke. DOCR hired a contracts liaison to research this issue and
help navigate contracts through the process. After meeting with repre-
sentatives from all CRUs, a common complaint emerged—the time from
completion of negotiations to getting Duke's institutional signature was
too long and not transparent. To better understand this issue, the con-
tracts liaison reviewed the average turnaround times to get institutional
signature, which was obtained in a separate central ofﬁce. By moving
the signature function to within DOCR, the average time to get institu-
tional signaturewas reduced from 3.6 days to 0.12 days.While the orig-
inal 3.6 days may not seem like a large delay, the improvement shows
that therewere inefﬁciencies in the process. DOCR streamlined required
components and made it a priority to get the contracts signed within
24 h of receipt. Additionally, DOCR provided frequent status updates if
there was a contract that could not be signed within 24 h and worked
with the team to shepherd it through the process and get it approved
for signature. This focus on turnaround time and customer service has
eliminated the complaints regarding the long wait for institutional sig-
nature. The contracts liaison continues to identify other areas of the
Table 1
Study startup metrics for ﬁscal years 2011–2015.
Fiscal
year
Number of protocols
approved
Median days from IRB submission to
institutional approval
Median days from institutional approval to ﬁrst
participant consented
Median days from IRB submission to ﬁrst
participant consented
2011 306 86 74 182
2012a 352 93 69 180
2013b 292 101 68 194
2014 296 92 52 161
2015 313 100 50 171
Note: Data are for clinical research studies that scheduled, ordered, or charged through the Duke University Health System.
a Transition to uniﬁed research support ofﬁce.
b Electronic health record implemented at Duke.
Table 2
Study closure metrics for ﬁscal years 2011–2015.
Fiscal
year
Median days from
institutional
approval to study
closurea
Number of
protocols
closed with no
consent
Number of
protocols
closed
(total)b
Percentage of
studies closing with
no consented
patients
2011 561 73 246 30%
2012c 449 67 323 21%
2013d 469 63 330 19%
2014 592 68 393 17%
2015 532 44 304 14%
Note: Data are for research studies that scheduled, ordered, or charged through the Duke
University Health System.
a Shorter time from institutional approval to study closure is consideredmore efﬁcient.
b These protocols did not necessarily open in the ﬁscal year indicated.
c Transition to uniﬁed research support ofﬁce.
d Electronic health record implemented at Duke.
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through each one to minimize inefﬁciencies and make the process as
transparent and user-friendly for study teams as possible.
Compliance with results reporting in ClinicalTrials.gov is another
area where DOCR has shown improvements. On-time reporting has in-
creased from b50% to 90% to 100% compliance over the past year.
3.2. Satisfaction
Satisfactionwith DOCR services is assessed by an annual survey sent
to individuals on the DOCR mailing list. The satisfaction rates have
remained at approximately 75% or higher throughout DOCR's history
(Fig. 3A). Similarly, the proportion of negative comments received
stayed relatively constant over time, with slightly more negative com-
ments in ﬁscal year 2014, perhaps corresponding to frustrations associ-
ated with the implementation of the electronic health record across the
health system (Fig. 3B). In addition, satisfaction for Research Manage-
ment Team services (data management and clinical research coordina-
tor support) is assessed via email or phone call after one month, and
then using a feedback survey sent after the effort has ended. Ratings
for this support over a 1-year period have been very positive (Fig. 3C,
D). In ﬁscal year 2015, of individuals evaluating their optional study
planning consultation (N = 16) and grant development assistance
(N=12), 94% and 100%, respectively, indicated theywould be extreme-
ly or quite likely to use the service again.
DOCR aims to hire high-performing staff and match appropriately
skilled and experienced individuals to study needs. If a performance
issue or mismatch occurs, this can be corrected quickly for the study
team with a replacement from DOCR, generally within 1 week. In this
model, investigators and study teams do not have to spend time hiring
or addressing performance issues themselves.
3.3. Cost
The operating budget of the narrowly scoped Clinical Research Sup-
port Ofﬁce prior to transition to DOCR was approximately $916,000 in
ﬁscal year 2012. In ﬁscal year 2015, DOCR had an operating budget of
$2.68 M, which included $905,000 covered by the CTSA grant. DOCR is
paid for as part of the indirect cost rate for clinical research, which has
not changed as a result of DOCR's inception. Only direct effort costs
are charged to studies; there is no charge for overhead,management, fa-
cilitation, or consultation. In 2015, DOCR's ResearchManagement Team
had gross costs of $1.3 M, all of which were covered by research grants
or contracts. From ﬁscal year 2012 to 2015, the institution's costs for
clinical research compliance and auditing (external to DOCR) remained
virtually unchanged, from $2.48 M to $2.45 M, not accounting for inﬂa-
tion. This was in spite of a growing number of research studies and pa-
tients enrolled (Table 3).
4. Discussion
Evenwhen the need for research administration is recognized, there
can be disagreements over the structure of support and responsibilityfor oversight. We have observed that the concept of “central” support
can be met with a negative reaction—the perception being that these
systems are heavy-handed and inﬂexible, consisting of top-down policy
and bureaucracy. Conversely, in our experience supporting research
teams, individualized approaches to research conduct throughout an in-
stitutionmay appear effective, or at least more expedient, but frequent-
ly lead to operational, regulatory, and compliance challenges.
In a transition to the uniﬁed support ofﬁce, we observed that a cul-
ture change from within research administration may help reduce bar-
riers to acceptance. To avoid creating infrastructure for the sake of
infrastructure, it was essential for DOCR to apply its efforts with the
mindset of optimizing clinical research while also protecting human
subjects from potential harm due to poor research conduct. Assessment
and reassessment of existing administrative processes was essential to
this process. Without thoughtful, multi-source input, development of
institutional policies and procedures may distract faculty from research
conduct and create a perception that administration is hampering re-
search progress.
A focus throughout DOCR's growth and development was on build-
ing relationships with clinical investigators and study teams. Demon-
strating advocacy for researchers by ﬁnding solutions that are
compliant with policies and regulations while allowing the research to
proceed expediently is the currency to support cultural change. Support
from senior leadership within the institution was also critical through-
out the ofﬁce's transition. By assuming the role of facilitator, DOCR em-
powers staff within study teams to speak up when an issue needs to be
addressed. This may not always be the case in decentralized structures
where a principal investigator is also the supervisor of an administrator
or coordinator.
Other consolidated units supporting clinical research at AMCs have
been detailed in the literature, but those have been typically imple-
mented at the level of a department or group of departments [15,16].
This paper describes experiences implementing a clinical research sup-
port ofﬁce for an entire AMC. As with DOCR, efﬁciencywas described as
a major goal of the previously published examples, though data to sup-
port the efﬁciency of such a model remain limited. In an analysis of
Table 3
Duke University School of Medicine active research studies and participants enrolled for ﬁscal years 2011–2015.
Fiscal
year
Total active
studies
NIH-sponsored
studies
Other federal
studies
Industry-sponsored
studies
Internal
studies
Total enrolling
studies
Total patients enrolled
on studies
Average patients enrolled per
enrolling study
2011 4988 1114 844 1136 1894 2171 18,371 8.5
2012a 5362 1170 887 1195 2110 2187 18,321 8.4
2013 5628 1230 933 1251 2214 2184 22,707 10.4
2014 5749 1250 965 1265 2269 2167 24,500 11.3
2015 5757 1239 1000 1292 2226 2104 24,355 11.6
a Transition to uniﬁed research support ofﬁce.
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Bogart and colleagues, characteristics included shared efﬁcient process-
es, continuous process improvements, and a business-like approach to
clinical research [17]. All of these are approaches employed by DOCR.
Moving to a uniﬁed research support ofﬁce involved an increase in
cost to the institution, which was expected, and has been described
with transitions at other institutions in association with increased ser-
vices [16]. However, during a period in which studies and enrollment
increased, compliance costs remained stagnant. If DOCR can prevent
compliance issues through training/education, consultation, and its
suite of support services ensuring high-quality research, this will be of
value to the institution. While some institutions approach shared sup-
port as a cost-savings measure, another view is to recognize research
administrative support as an investment, with returns in the form of in-
creased collaboration and retention of clinical investigators through the
delivery of high-quality services [18].
A limitation in our analysis is that formal satisfaction data are only
available starting after the establishment of DOCR. Improvements in
study startup times have only begun to be observed, andwewill contin-
ue to monitor these and other study metrics to gain a better under-
standing of the effects of the support ofﬁce. Rollout of a clinical
research management system within the next year will provide access
to more data for assessing changes in efﬁciency and return on invest-
ment for DOCR. It is unknown how long it would take to observe such
changes. DOCR, alongwith CTSA administrators, is working on assessing
common metrics, both within and across institutions [19]. Currently,
this remains challenging with varying systems to collect and analyze
data. As new electronic systems (such as the clinical research manage-
ment system) are deployed, these common data elements can be cap-
tured to standardize data collection across the institution for all studies.
4.1. Remaining challenges
While signiﬁcant strides have been made to improve clinical re-
search oversight and operational support at Duke, there is much to do.
In some areas, trust between faculty and administration must be re-
established due to previously over-burdensome processes. Some inves-
tigators prefer to maintain their individualized approaches to
conducting research. Havingmanyof DOCR's services categorized as op-
tional allows some ﬂexibility while still providing overarching structure
and support. Since the ofﬁce evolved gradually, there is still some dupli-
cation with remaining CRU support, but this is expected to shift over
time. Keeping focused on the ultimate goal of improving patient care
and continuing to foster collaborationswill help administration and fac-
ulty move forward as a team. Shifting a decades-long investigator/coor-
dinator research culture to this collaborative approach between central
administration and a study team requires communication, trust, and a
willingness to accept component responsibilities at all levels of a re-
search organization. As the role of research professionals is increasingly
professionalized, it should bemore widely recognized that helping nav-
igate the research environment is a valuable, high-level skill. In addition,
DOCR,while successful in providing an increased range of services,must
be mindful to grow responsibly and not just for the sake of growth. Fi-
nally, wemust continue to share experiences to cultivatemore effectiveresearch administration, particularly throughout the CTSA institutions,
to transform the clinical trial enterprise.5. Conclusion
The Duke Ofﬁce of Clinical Research provides one example of how
uniﬁed research support can be implemented within a large AMC. Al-
though uniﬁed research administration and support is often met with
negative reactions initially, we have shown that it is possible to devel-
op a team that cares and delivers excellent customer service to over-
come this perception. The uniﬁed model has multiple advantages that
can be realized through a shift in culture to refocus effort on the efﬁ-
cient and safe conduct of research that can lead to improved patient
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